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Abstract 
The idea that different patients will respond differently to the same treatment is not new.  
The recent advances in genomics and laboratory medicine have led to the hope that it will 
be possible to maximise the benefit and minimise the harms of each medical therapy by 
using an individuals’ biomarker status to ‘personalise’ their treatment. The selection of 
treatment for each individual would then be determined, not just by their disease status (or 
an estimate of the risk of developing a disease or disease progression), but also by their 
genetic make-up or by other measurable characteristics, such as the level of a particular 
biomarker in the blood. This review discusses the extent to which personalised medicine 
might be applied in stroke, and the implications for global stroke health care. 
 
 
Introduction 
How plausible is this concept? There is a considerable variation in opinion about its likely 
current and future clinical impact of personalised medicine, ranging from the wildly 
optimistic1 to the more cautious.2, 3 However, whatever the benefits, widespread 
implementation of personalised medicine will have huge financial, ethical, regulatory and 
other implications for all stakeholders.4  If the stroke community ‘get it right’, wise and wide 
application of personalised medicine might contribute to reducing the global burden of 
stroke. If we get it wrong, there is scope for huge waste and greater global stroke health 
inequality.
5
  
 
Terminology 
Personalised medicine
4
  means tailoring the management of an individual person to the 
characteristics of their disease or biology, by the use of diagnostic technology to target 
treatment or to modify the treatment itself to   maximise benefit and minimise harm (e.g. by 
the use of pharmacogenomics to tailor the dose, choice of agent or other aspect of drug 
delivery).
4
 Stratified medicine operates at the level of groups of people, identified by a 
particular set of characteristics, and is defined by the US Food and Drug Administration 
(FDA) as: ‘Using a biomarker to match a patient to a cohort that has exhibited a differential 
response to a treatment.’
6
  Precision medicine is an analogous term recently given 
prominence by President Obama and is ‘intended to avoid the implication that medications 
would be synthesized personally for single patients and to convey a broader concept that 
would include precisely tailoring therapies to subcategories of disease, often defined by 
genomics’.
7
  
 
Methods of this review 
Aims. The aims of this review were to: a) search the literature for papers relevant to stroke, 
cerebrovascular disorders and cardiovascular medicine, b) review relevant publications and 
identify the key clinical and methodological themes and c) summarise implications for 
current and future clinical practice and research in an attempt to answer the question posed 
in the title. 
 
Protocol:  there is no formal protocol for this narrative review, but where appropriate, I have 
tried to meet the criteria set out in the PRISMA checklist for systematic reviews.
8
 
 
Search. A structured MEDLINE search of the literature; MEDLINE Search terms: 
(*Pharmacogenetics/ or *Individualized Medicine/ or personalised medicine.mp. or stratified 
medicine.mp.or precision medicine.mp or precision medicine.mp. or *Molecular Targeted 
Therapy/) and (Stroke, Lacunar/ or exp *Stroke/ or stroke.mp or cerebrovascular disorders). 
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The MEDLINE search yielded 94 potential papers. Material in this report is drawn from a 
variety of additional sources; I scanned the bibliography of the reports selected for inclusion 
in this article; the bibliography of the Wikipedia entry on Personalised Medicine;9 the 4th 
Edition of the Personalised Medicine Coalition’s publication;
10
 the  BMC Medicine collection 
of articles on Personalised Medicine11; the 2013 report of the FDA ‘Paving the way for 
personalised Medicine’6; and searches of my personal files. 
 
Data extraction and risk of bias.  Without using formal qualitative research methods, I have 
extracted some key themes and the papers relevant to that theme. Risk of bias and conflict 
of interest are difficult to judge objectively, but are mentioned where necessary. 
 
Outcome criteria for ‘personalisation’.  My criterion for accepting that a method for 
personalising treatment is truly ‘effective’ is that there is clear evidence:  
 
a) that the ‘personalising’ test provides reliable guidance on prognosis, and 
b) that the test performs better than clinical judgement, preferably when added to a 
validated prognostic score, and preferably also 
c) of a significant quantitative marker x treatment effect interaction.
12
   
 
In other words, the test reliably identifies that a patient identified ‘positive’ by the test will 
clearly respond better (or clearly worse) than those tested ‘negative.’  This is referred to as 
‘effect modification’ or treatment interaction.  Many factors influence prognosis, but 
markers that can identify groups where there is a clinically significant degree of effect 
modification are uncommon.13, 14   
Breast cancer oestrogen receptor (ER) status as a biomarker of treatment-responsiveness  
In 1988, the Early Breast Cancer Trialists Collaboration published a meta-analysis of the anti-
oestrogen agent tamoxifen for the long-term treatment of breast cancer.15 The analysis 
included data from 28 trials on 16,513 women of whom 4000 had died.  About half the 
women had had ER status (ER rich or ER poor) determined at baseline; those with ER poor 
status had a worse prognosis, but ER status did not identify a group wholly unresponsive to 
tamoxifen.
16
 While these early studies included very large numbers of women and a large 
number of deaths, the sample size was not sufficient to confirm that women with breast 
cancer who were ‘ER poor’ would not gain sufficient benefit from the drug to justify the 
significant anti-oestrogen side-effects. However, with the accumulation of more trials and 
longer term follow-up, an updated meta-analysis in 1998 with data on 37,000 women from 
55 trials concluded ‘For women with tumours that have been reliably shown to be ER-
negative, adjuvant tamoxifen remains a matter for research. However, some years of 
adjuvant tamoxifen treatment substantially improves the 10-year survival of women with 
ER-positive tumours… with the proportional reductions in breast cancer recurrence and in 
mortality appearing to be largely unaffected by other patient characteristics or 
treatments.’15    This example shows how difficult it can be, even for a common disease like 
breast cancer, that has been studied in large-scale long-term randomised trials, to identify 
and characterise the importance of a biomarker in prognosis (evident in the 1988 paper) and 
even harder to determine its importance as a valid and reliable marker of treatment 
response (in this case, it took an additional 10 years of clinical trial data collection to 
establish that fact). Put simply, to determine reliably that a biomarker x treatment 
interaction exists requires an enormous amount of data. 
Genomic analysis to select patients with cancer or infectious disease 
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There are now quite a number of examples where genomic testing to personalise treatment 
have been (or could be) applied.  The Personalized Medicine Coalition has published a list of 
examples10 and it is striking that many are drawn from cancer or infectious disease.  In 
patients with non-small cell lung cancer (NSLC), clinical trials have established that, among 
patients with mutations in the epidermal growth factor tyrosine kinase receptor (EGFR-TK), 
the EGFR-TK inhibitors gefitinib and erlotinib target specific cancer cells and are more 
effective and less toxic than standard chemotherapy regimens.
17
 The value of diagnostic 
testing depends on the mutation frequency in the population; EGFR activating mutations 
occur in approximately 10% of Caucasian patients with NSCLC and up to 50% of Asian 
patients.9 From the perspective of the UK NHS, personalised medicine must also be cost-
effective; as it happens, identifying NSLC patients with EGFR mutations to select for 
treatment has proved cost-effective.17  In the field of infectious disease, in patients requiring 
antiretroviral therapy with abacavir, those who carry the HLA-B*57:01 allele are at high risk 
of experiencing a severe hypersensitivity reaction to the drug. In predominantly white 
populations, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for this 
serious adverse reaction, but among the remaining 6% with the allele, the test has sufficient 
sensitivity and specificity to justify avoiding the use of abacavir and using alternative 
antiretroviral agents. Thus pharmacogenetic testing can be used both to maximise benefit 
and reduce harm from a drug in settings where testing is affordable. 
 
Applicability of personalised medicine for stroke and cardiovascular disease 
In stroke medicine, we have a number of simple tools that effectively stratify patients and 
identify groups of patients most likely to benefit from treatment: degree of carotid stenosis 
in patients with carotid territory transient ischaemic attack, risk scores for patients with 
atrial fibrillation and onset to treatment time in acute ischaemic stroke. However, stroke and 
cardiovascular medicine are, a priori, perhaps less susceptible to genomic approaches, for 
several reasons, but chiefly that the proportion of common cardiovascular disorders that are 
attributable to a single gene mutation is small and the already identified genetic common 
risk variants explain only a small proportion of overall stroke risk.
3
  Although the discovery of 
highly effective biomarker-targeted therapies could be beneficial for a small number of 
individuals, the population–level impact on reducing the global burden of disease is likely to 
be small.  Secondly, if commonly used therapies are to be targeted on those most likely to 
benefit and least likely to be harmed, then all patients will need to undergo (potentially 
expensive) biomarker characterisation before treatment is initiated.  If that is the case, the 
pre-treatment testing must provide a high degree of discrimination and perform significantly 
better than targeting strategies based on simple clinical risk scores or basic laboratory data.  
 
Stroke and cardiovascular disease  
Risk scores to target drug-based Diabetes Mellitus prevention therapies? 
Diabetes mellitus is a major risk factor for cardiovascular disease and stroke.  Patients with 
impaired glucose metabolism, at high risk of developing diabetes, have substantial variation 
in their likelihood of receiving benefit from diabetes prevention treatments.
18
 The Diabetes 
Prevention Program compared the impact of two different lifestyle interventions with 
lifestyle intervention plus metformin therapy on the development of new onset diabetes 
mellitus.18 In a post hoc-analysis, the authors sought to determine whether some 
participants in the Diabetes Prevention Program were more or less likely to benefit from 
metformin.18  They developed a diabetes risk model and found that the benefit of metformin 
was seen almost entirely in patients in the top quarter of risk of diabetes who averaged a 
21.4% three year absolute risk reduction (number needed to treat 4.6), and no benefit was 
seen in the lowest risk quarter. Of course, decision making must be based on an accurate, 
simple, reliable and externally validated risk prediction tool.  If, this tool were validated and 
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widely applied, it could target drug therapy on those most likely to benefit,  decrease 
overtreatment, and make prevention of diabetes far more efficient, effective, and patient-
centred.   
 
 
 
Target folate therapy on hypertensive patients according to MTHFR genotype and baseline  
folate levels?  
Methylenetetrahydrofolate reductase (MTHFR) is the main regulatory enzyme for folate 
metabolism. Polymorphism of the MTHFR gene C677T leads to a reduction in enzyme 
activity, resulting in decreased folate levels.  Low folate levels are a modest risk factor for 
coronary heart disease (CHD) and stroke.19 A meta-analysis of observational studies showed 
that individuals with the MTHFR 677 TT genotype had a significantly higher risk of coronary 
heart disease, particularly in the setting of low folate status.
20
  Despite this background, 
folate supplementation for stroke prevention has –up to now - been controversial, and a 
series of trials testing the hypothesis did not provide clear evidence of benefit.21 Recently, 
the large-scale trial CSPPT study in China (a population without folic acid fortification), aimed 
to assess the joint effects of baseline folic acid and MTHFR C677T genotype  on response to 
folic acid supplementation added to antihypertensive therapy for primary stroke 
prevention.22   All subjects had MTHFR C677T genotype determined before study entry and 
treatment allocation was stratified by genotype (CC, CT, or TT). The study included over 
20,000 subjects with hypertension, and showed clear evidence of a reduction in stroke with 
folate supplementation. Though there was no significant interaction of treatment effect with 
baseline folate level, the authors noted – as might be expected - that the greatest reduction 
in stroke appeared to be greatest in patients in the lowest quarter of baseline folate levels.
22
 
The results from the joint analyses of MTHFR genotype and baseline folate level showed that 
among participants with the CC or CT genotypes, the highest risk of stroke and the greatest 
benefit of folic acid therapy were in those with the lowest baseline folate levels. In addition, 
the data suggested that individuals with the TT genotype may require a higher dosage of 
folic acid supplementation to overcome biologically insufficient levels.22  While these data 
are of biological interest, the practical implications are limited.  For a low-cost, non-toxic 
therapy like oral folate, folate supplementation of relevant foodstuffs for the general 
population would be more likely  to yield greater population health gain than folate therapy 
targeted on individuals selected by  genotype and folic acid level. 
 
Genetically –determined dosing of clopidogrel?  
Antiplatelet therapy is a cornerstone of drug treatment for stroke prevention. Bedside 
testing of blood or genetic biomarkers have been suggested as a way to maximise 
antiplatelet drug efficiency.
23
  Variation in response to clopidogrel is partly determined by 
genetic factors, and CYP2C19 genotyping has been considered potentially helpful in dose-
selection, but a systematic review and meta-analysis found that, in effect-modification 
studies, CYP2C19 genotype was not associated with modification of the effect of clopidogrel 
on cardiovascular disease end points or bleeding (P >0.05 for interaction for both).
24
  
 
Genetically –determined dosing of Warfarin? 
 Oral anticoagulation in patients with atrial fibrillation is an effective form of stroke 
prevention, but the (partly genetically-determined) inter-individual variation in dosing 
requirements of warfarin makes it difficult to establish a therapeutic level of anticoagulation 
rapidly and efficiently.
23
 An algorithm for estimating the appropriate warfarin dose that is 
based on clinical and genetic data has been developed and validated, and provided 
significantly better predictions of appropriate dose of warfarin than either the clinical 
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algorithm or a fixed-dose approach.{The International Warfarin Pharmacogenetics 
Consortium, 2009 12989 /id} However, a formal cost-effectiveness model has shown that, 
given the additional cost of genotype testing (currently bout US $ 400 per person), this 
strategy is unlikely to be cost-effective for typical patients with non-valvular AF, but may be 
cost-effective either in patients at high risk for haemorrhage who are starting warfarin 
therapy, or if the cost of the genetic test falls substantially.26   
 
Brain imaging to personalise therapy in atrial fibrillation (AF)? 
A review of the role of MR brain imaging to stratify bleeding risk and stroke risk to optimise 
treatment of patients with AF concluded that, while MR is promising in this role, large scale 
trials are needed to determine its effectiveness and cost-effectiveness.
27
 Looking to the 
future, the Atrial Fibrillation competence NETwork/European Heart Rhythm Association 
(AFNET/EHRA) consensus conference identified several potential methods that might allow 
more personalized management of AF beyond the traditional risk scores:  integrating atrial 
morphology and damage; genetic predisposition; markers of systemic or local inflammation, 
and markers of cardiac strain.28 
 
Avoiding statins in people at high risk of myopathy? 
There is strong evidence that lowering LDL-cholesterol reduces the risk of cardiovascular 
events, and the Cholesterol Treatment Trialists Collaboration concluded ‘In individuals with 
5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL 
cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 
over 5 years. This benefit greatly exceeds any known hazards of statin therapy.’
29
 It has been 
argued that the population health benefit will be greatest with a policy of ‘statins for all over 
the age of 50.’
30
 Personalising such therapy to reduce the harms of treatment, would require 
population-wide genetic testing of all people aged over 50 to identify the small number of 
patients with the SLCO1B1 variant who are at high risk of statin induced myopathy;31 not an 
attractive or cost-effective prospect! 
 
Clinically-stratified and targeted antithrombotic therapy for acute ischaemic stroke? 
Patients with acute ischaemic stroke are at high risk of arterial and venous thromboembolic 
events that can significantly worsen outcome, yet immediate administration of antiplatelet 
or anticoagulant agents may, by increasing the risk of haemorrhagic events, negate any 
benefit.32, 33 Two recent individual patient data meta-analyses of large-scale trial data have 
addressed whether stratification by the use of clinical risk scores might lead to better 
targeting of antithrombotic therapy with either aspirin or heparin
34, 35
 in patients with acute 
ischaemic stroke. Unfortunately, none of the risk scores evaluated had sufficient 
discriminative power to be clinically useful.34, 35  
 
Clinical or imaging targeting of intravenous thrombolysis for acute ischaemic stroke? 
At present, the most important stratification tool for patient selection is the clinical history 
(to determine whether time from symptom onset is less than about 4.5 hours).
36
 The use of 
risk scores, either to avoid treatment in people with high a risk of bleeding or select those 
with the greatest likelihood of benefit, is again beset with the problem that none of the risk 
scores have the discriminative power to be clinically useful.37  The role of brain imaging is 
chiefly to exclude intracranial haemorrhage as the cause of the stroke. There are some 
imaging features that provide an additional degree of guidance; the pre-treatment scan 
appearance can predict prognosis,38 and there is a significant interaction of extensive early 
ischaemic acute changes with the risk of intracranial bleeding.
39, 40
 However, the extent of 
early ischaemic change did not interact with the effect of treatment on functional 
outcome.40 In addition, some pre-stroke scan findings (such as atrophy and old infarcts) a 
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have clear effect on modifying the response to thrombolysis.
41
 The role of advanced brain 
parenchymal, blood vessel and tissue perfusion imaging  to personalise reperfusion and 
other acute therapies is worthy of a review in its own right.42  There has been an extensive 
search for other blood and imaging biomarkers to supplement clinical tools, but none have 
yet proved robust enough for clinical use.42  A model based on clinical and genetic factors 
has shown some promise as a tool to predict symptomatic intracranial haemorrhage and 
death, but the study begs the question as to whether genotyping could ever be done fast 
enough to guide thrombolysis.
43
 
  
Scores, brain imaging, or other biomarkers to target stroke rehabilitation? 
Rehabilitation is a huge field that is advancing rapidly, so just to give a flavour of the current 
state of affairs, I will focus on just one topic; interventions targeted at improving upper limb 
function.  To start with, the best predictor of recovery of arm function after stroke is the 
severity of the initial stroke, and there is – as yet - little evidence that more complex clinical 
scores are any better.
44
     As to therapy for improving arm function, a 2014 Cochrane 
‘overview of reviews’ identified 40 completed reviews (containing 503 studies and 18,078 
participants), covering 18 individual interventions.45  The authors concluded ‘there was 
moderate-quality evidence supporting the benefit of constraint-induced movement therapy 
(CIMT), mental practice, mirror therapy, interventions for sensory impairment, virtual reality 
and a relatively high dose of repetitive task practice, suggesting that these may be effective 
interventions.’  However, there was no evidence of a score or biomarker that reliably 
predicted the response to these therapies. Yet, the development of animal models of post-
stroke recovery, advanced neuroimaging and brain stimulation techniques and other 
advances offer the promise that basic science research will provide better tools to develop, 
refine and target rehabilitation therapies.  For example, structural brain imaging with 
automated MRI scan analysis46 and an algorithm combining baseline measures of arm 
strength and response to transcranial magnetic stimulation can help predict recovery of arm 
function at 3 months.
47
  While predicting prognosis is helpful, identifying markers of 
response to treatment is more important; structural brain imaging
48
 and a functional MRI 
show promise in selecting ‘dose’ of robotic arm therapy to promote motor recovery.49   
 
Can personalised medicine be tested in trials? 
Treatments with very large effects are rare in medicine, most have only moderate effects, 
and to detect such moderate effects reliably requires trials with very large sample sizes.13 
The best estimate of a relative treatment effect in an individual is the overall effect seen in a 
large trial or meta-analysis of large trials.
13, 14
 Trying to determine whether a patient with a 
particular characteristic (e.g. having a particular genetic mutation) really will respond much 
better or much worse  (or not at all) to the treatment than the ‘average’ is difficult. This 
property of modifying the effect of a treatment is detected by a statistical test for 
interaction.50  Interactions can be quantitative   (treatment is effective in both subgroups, 
but clearly more effective in one than the other) or qualitative (treatment is clearly 
beneficial in one subgroup and clearly harmful in the other).  Reliable detection of true 
subgroup interactions even in very large meta-analyses requires both cautious interpretation 
and analyses that have substantial statistical power.13, 14, 51  As Richard Peto puts it, in the 
context of personalised medicine for breast cancer, ‘questions about such interactions are 
easy to ask, but difficult to answer.’
14
  If it has been difficult in cancer medicine, I think the 
literature reviewed here suggests it will be even harder in stroke medicine.  
 
Current implementation in clinical guidelines 
While there are many suggestions about risk stratification tools, their implementation in 
practice is less well studied. A review of clinical practice guidelines for common diseases 
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(heart disease and stroke prevention, diabetes and breast cancer), sought to identify how 
evidence on the value of risk stratification tools was incorporated in the guideline.52  The 
review included 133 guidelines but found that only a small proportion made risk-stratified 
treatment recommendations that were well supported by appropriate evidence.
52
  It is clear 
that there will be many ethical, regulatory, financial and societal aspects to be dealt with in 
research and in clinical implementation of personalised medicine.4   
 
 
Cautions on personalised medicine especially for low- and middle-income countries  
Coote reminds us that wide implementation of personalised medicine could distract from 
low-cost and effective population-wide interventions and so may not be the route to a 
healthy world.2  There is a danger that expensive hospital-focused medicine will draw 
resources away from disease prevention and long-term care for chronic diseases.5 In low- 
and middle-income countries, therefore, access to personalised medicine for the wealthy 
few may have adverse consequences for the care of the many less well-off citizens in the 
country.  
 
Conclusion 
Methods for tailoring therapy for the prevention, acute treatment or rehabilitation of each 
individual stroke patient are at an early stage of development.  In the near future, 
personalised medicine seems unlikely to make a major contribution to reducing the global 
burden of stroke and so – as stroke clinicians -  we should focus on implementing 
interventions that are known to be effective (which  and that will give us plenty of work to 
do for now). In the meantime, research teams must continue to study whether, and how to 
tailor the treatment to the patient more effectively than we do at present. 
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